Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics

Diagnostic Pathology

Yunshan Wang¹  Yuping Sun⁵  Butong Ding²  Jingnan Wang⁷  Fei Qv⁶  Chuanwu Qiao³  Yan Zheng¹  Xiangdong Liu⁴ 

[1] Shandong Province Key Laboratory for Target Molecule, Jinan, China;Medical Research & Laboratory Diagnostic Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, China;Department of Pharmacy, Jinan Central Hospital Affiliated to Shandong University, Jinan, China;Key Laboratory for Reproductive Medicine of Shandong Province, Provincial Hospital Affiliated to Shandong University, Jinan, China;Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China;Department of Pathology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China;Current Affiliation: Department of Thoracic Surgery, Cancer Insititute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

关键词: Prognosis;    Tumor histological grade;    HR;    HER2;    SATB1;    Breast cancer;   

Others  :  1214029
DOI  :  10.1186/s13000-015-0282-4

 received in 2015-02-07, accepted in 2015-04-16,  发布年份 2015

【 摘 要 】

Background

Special AT-rich sequence binding protein 1 (SATB1) is found acting as a “genome organizer” that functions as a landing platform to regulate tissue-specific gene ex-pression. In breast cancer cell lines it has been proven that SATB1 could upregulate the expression of the HER2. In this paper, the relevance of SATB1 and HER2 expression was assessed in human breast cancer tissues, and their influence on tumor histological grade and patients’ survival was explored.

Methods

Using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), 169 patients with breast cancer were assessed for SATB1 expression, HER2 amplification and hormone-receptor (HR) expression. The effects of SATB1 expression on HER2 and HR expression as well as their association with clinicopathologic characteristics were further analyzed by statistical evaluation.

Results

SATB1 expression was correlated with HER2 expression in breast cancer(r = 0.191; p = 0.013). SATB1, HER2 and SATB1/HER2 co-expression was negatively correlated with HR expression (r = −0.228, p = 0.003; r = −0.338, p = 0.000; r = −0.527, p = 0.000, respectively). SATB1 and HER2 single positive and their co-expression were all significantly correlated with higher histological grade (r = 0.239, p = 0.002; r = 0.160, p = 0.038; r = 0.306, p = 0.003, respectively). Multivariate cox regression analyses showed that SATB1 and HER2 were independent risk factors for breast cancer patients, while HR was a protective factor for patients’ survival. Comparing to SATB1 or HER2 single positive expression, SATB1/HER2 co-expression tended to have even worse prognosis.

Conclusions

SATB1 and HER2 performed a synergistic effect in breast cancer. Their expression correlated with poorly differentiated breast cancer and indicated an unfavorable prognosis.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1400555050159723 webcite.

【 授权许可】

   
2015 Liu et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Purbey PK, Singh S, Notani D, Kumar PP, Limaye AS, Galande S. Acetylation-dependent interaction of SATB1 and CtBP1 mediates transcriptional repression by SATB1. Mol Cell Biol. 2009; 29(5):1321-37.
• [2]Patani N, Jiang W, Mansel R, Newbold R, Mokbel K. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int. 2009; 9:18. BioMed Central Full Text
• [3]Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008; 452(7184):187-93.
• [4]Cheng C, Lu X, Wang G, Zheng L, Shu X, Zhu S et al.. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS. 2010; 118(11):855-63.
• [5]Chen H, Takahara M, Oba J, Xie L, Chiba T, Takeuchi S et al.. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. J Dermatol Sci. 2011; 64(1):39-44.
• [6]Zhou LY, Liu F, Tong J, Chen QQ, Zhang FW. Expression of special AT-rich sequence-binding protein mRNA and its clinicopathological significance in non-small cell lung cancer. J Southern Med University. 2009; 29(3):534-7.
• [7]Agrelo R, Souabni A, Novatchkova M, Haslinger C, Leeb M, Komnenovic V et al.. SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev Cell. 2009; 16(4):507-16.
• [8]Ross JS, Fletcher JA. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist. 1998; 3(4):237-52.
• [9]Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology. 2001; 61 Suppl 2:67-72.
• [10]Azizun N, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev. 2008; 9(4):553-6.
• [11]Hussein MR, Abd-Elwahed SR, Abdulwahed AR. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Cell Biol Int. 2008; 32(6):698-707.
• [12]Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z et al.. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003; 95(2):142-53.
• [13]Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M et al.. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 2013; 39(8):935-46.
• [14]Kato S, Masuhiro Y, Watanabe M, Kobayashi Y, Takeyama KI, Endoh H et al.. Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells. 2000; 5(8):593-601.
• [15]Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011; 29(33):4452-61.
• [16]Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005; 123(4):541-6.
• [17]Yanagisawa J, Ando J, Nakayama J, Kohwi Y, Kohwi-Shigematsu T. A matrix attachment region (MAR)-binding activity due to a p114 kilodalton protein is found only in human breast carcinomas and not in normal and benign breast disease tissues. Cancer Res. 1996; 56(3):457-62.
• [18]Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S et al.. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer. 1990; 65(8):1794-800.
• [19]Li QQ, Chen ZQ, Xu JD, Cao XX, Chen Q, Liu XP et al.. Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci. 2010; 101(1):80-6.
• [20]Pu X, Shi J, Li Z, Feng A, Ye Q. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer. Pathol Res Pract. 2015;211(6):412–5.
• [21]Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al.. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013.
• [22]Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al.. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clinical Oncol. 2010; 28(16):2784-95.
• [23]Marianna Sasso FB, Ciravolo V, Tagliabue E, Campiglio M. HER2 splice variants and their relevance in breast cancer. J Nucleic Acid Invest. 2011; 2(9):52-8.
• [24]Devilee P, Cornelisse CJ. Genetics of human breast cancer. Cancer Surv. 1990; 9(4):605-30.
• [25]Cai S, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet. 2003; 34(1):42-51.
• [26]Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ, Botchkarev VA, Kohwi Y. Genome organizing function of SATB1 in tumor progression. Semin Cancer Biol. 2013; 23(2):72-9.
• [27]Heubner M, Kimmig R, Aktas B, Siffert W, Frey UH. The haplotype of three polymorphisms in the promoter region impacts survival in breast cancer patients. Oncol Letters. 2014; 7(6):2007-12.
• [28]Purdie CA, Baker L, Ashfield A, Chatterjee S, Jordan LB, Quinlan P et al.. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br J Cancer. 2010; 103(4):475-81.
• [29]Davoli A, Hocevar BA, Brown TL. Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol. 2010; 65(4):611-23.
• [30]Papavasileiou D, Tosios K, Christopoulos P, Goutas N, Vlachodimitropoulos D. Her-2 immunohistochemical expression in oral squamous cell carcinomas is associated with polysomy of chromosome 17, not Her-2 amplification. Head Neck Pathol. 2009; 3(4):263-70.
• [31]Garcia-Becerra R, Santos N, Diaz L, Camacho J. Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance. Int J Mol Sci. 2012; 14(1):108-45.
• [32]Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology. 2001; 61 Suppl 2:73-82.
• [33]Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L et al.. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995; 10(12):2435-46.
• [34]Kobierzycki C, Wojnar A, Dziegiel P. Expression of SATB1 protein in the ductal breast carcinoma tissue microarrays - preliminary study. Folia Histochem Cytobiol. 2013; 51(4):333-8.
• [35]Ye CS, Zhou DN, Yang QQ, Deng YF. Silencing SATB1 influences cell invasion, migration, proliferation, and drug resistance in nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2014; 7(3):914-22.
• [36]Zhang H, Su X, Guo L, Zhong L, Li W, Yue Z et al.. Silencing SATB1 inhibits the malignant phenotype and increases sensitivity of human osteosarcoma U2OS cells to arsenic trioxide. Int J Med Sci. 2014; 11(12):1262-9.